Martin Driscoll

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA.

Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ

Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ.

Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA.

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

Asmacure Ltée develops novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company was founded by Yvon Cormier and Evelyne Israel-Assayag in 2002 and is headquartered in Quebec, Canada.